Fifth Third Wealth Advisors LLC Trims Stock Position in Novo Nordisk A/S (NYSE:NVO)

Fifth Third Wealth Advisors LLC trimmed its holdings in Novo Nordisk A/S (NYSE:NVO) by 14.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,115 shares of the company’s stock after selling 544 shares during the quarter. Fifth Third Wealth Advisors LLC’s holdings in Novo Nordisk A/S were worth $268,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Peoples Financial Services CORP. boosted its stake in shares of Novo Nordisk A/S by 9.4% in the fourth quarter. Peoples Financial Services CORP. now owns 8,449 shares of the company’s stock worth $727,000 after buying an additional 727 shares during the last quarter. Pines Wealth Management LLC purchased a new stake in Novo Nordisk A/S in the 4th quarter worth approximately $331,000. GuoLine Advisory Pte Ltd grew its stake in shares of Novo Nordisk A/S by 20.5% during the 4th quarter. GuoLine Advisory Pte Ltd now owns 346,500 shares of the company’s stock worth $29,806,000 after purchasing an additional 58,900 shares during the period. Wallace Advisory Group LLC increased its holdings in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Wallace Advisory Group LLC now owns 11,641 shares of the company’s stock valued at $1,001,000 after purchasing an additional 930 shares in the last quarter. Finally, Signal Advisors Wealth LLC lifted its stake in shares of Novo Nordisk A/S by 39.1% in the 4th quarter. Signal Advisors Wealth LLC now owns 15,874 shares of the company’s stock valued at $1,365,000 after purchasing an additional 4,464 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of NYSE:NVO opened at $78.74 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $78.17 and a 1 year high of $148.15. The firm has a market capitalization of $353.33 billion, a PE ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45. The business’s 50 day moving average price is $98.33 and its 200-day moving average price is $117.69.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on NVO. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.